Pre-Made Ensovibep biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Severe?acute?respiratory syndrome?coronavirus?2 RBD for drug discovery and mechanism of action (MOA) research

Pre-Made Ensovibep biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Severe?acute?respiratory syndrome?coronavirus?2 RBD is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ensovibep is a DARPin therapeutic candidate, designed specifically to inhibit target cell entry of SARS-CoV-2, the virus that causes COVID-19. DARPins (Designed Ankyrin Repeat Proteins) are mono or multi-specific protein-based therapies, designed to specifically engage their targets for various effects. Ensovibep includes three covalently linked individual DARPin domains which bind to the spike protein of SARS-CoV-2. With these domains incorporated into a single molecule, ensovibep is designed to block the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, even in the presence of some mutations of the spike protein. Several characteristics of DARPin therapeutics make them potentially suitable for COVID-19 treatment, including multi-specific binding, the rapid onset of action, and scalable bacterial production.